Treatment of tissue injury caused by ischemia-reperfusion with new peptide

December 24, 2014 / Bio Valley / recently, a team at Kansas State University has demonstrated that the use of a peptide can prevent or reduce intestinal tissue damage The team's ongoing work could have far-reaching implications, including new approaches to treating heart attacks or strokes, as well as cancer Sherry Fleming, associate professor of biology, said: therapeutic polypeptide (B2 glycoprotein I peptidase inhibitor) or amino acid chain developed by Kansas State University can reduce or prevent intestinal tissue damage caused by blood and oxygen reduction, i.e ischemic damage When the affected tissue recovers blood flow (reperfusion), peptides have also been shown to be effective, and reperfusion is usually more damaging than ischemia When the cell is ischemic, there is a new molecular marker on the cell surface, which actually tells the body's immune system that there is a problem with the cell However, in the process of reperfusion, the immune system acts like a "drama queen", which overreacts So the researchers hope to find a way to keep therapeutic peptides bound only to markers (ischemic regions) We've designed therapeutic peptides that don't bind at will, but that bind to very specific ischemic regions At present, there are no drugs available for the treatment of reperfusion ischemia, and this therapeutic peptide has been shown to reduce tissue damage and animal mortality Peptide developed by Kansas State University is considered safe compared to other potential therapeutic agents for ischemia-reperfusion because it does not damage the immune system of patients It is also more efficient, with lower manufacturing costs If proven to be effective, the peptide will reduce tissue damage caused by heart attacks, strokes or trauma in humans and animals This article is the original compilation of Biovalley, welcome to reprint! Please indicate the source of the reprint and attach the original link Thank you! Researchers hope patient can pay way to future treatments of heart, lung disease